The immunomodulatory drug lenalidomide repairs the LFA-1 – mediated motility defect in CLL patient T cells. (A) Phase-contrast images (original magnification ×20) show untreated (top) and lenalidomide (Lenalid.) (1μM)–treated (bottom) CD3 T cells from CLL patients, which were adhering to immobilized CD54 ligand for 10 minutes following exposure to chemokine CXCL12. The enlarged image (inset) shows an individual cell from a representative experiment. Video microscopy recorded the migration on CD54 for 20 minutes before tracking and analysis. Representative migratory tracks of individual T cells from untreated compared with Lenalid.-treated CLL samples are shown in (B) the upper plots (n = 40 cells per patient experiment). (C) Box-and-whisker plot analysis of 12 independent CLL patient migration experiments is shown in the bottom box plots. **P < .01. ns, nonsignificant findings.